Data were presented previously at the 2010 Joint International Neurogastroenterology and Motility Meeting in Boston, Massachusetts, USA on 26-29 August 2010 and published as an abstract [Vazquez-Roque M, Camilleri M, Carlson P, McKinzie S, Murray JA, Burton D, Zinsmeister AR. HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome.
Background Colonic transit (CT) is accelerated in 46% of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Improvement in IBS-D with gluten withdrawal is associated with human leukocyte antigen (HLA)-DQ2 positivity; the mechanism of improvement is unclear.
Objective To determine if HLA-DQ2-positive or HLA-DQ8positive patients with IBS-D have faster small bowel (SB) or CT than HLA-DQ2-negative and HLA-DQ8-negative patients.
Materials and methods Among 94 patients with IBS-D, who previously provided DNA samples, 64 had undergone validated measurements of CT [geometric center at 24 h (GC24)]; 50 of the patients also had measurement of gastric emptying (GE) and 54 of SB transit (colonic filling at 6 h). HLA-DQ status was determined by tag single nucleotide polymorphism approach. Associations of colonic filling at 6 h and GC24 with HLA-DQ2 and HLA-DQ8 status were assessed using analysis of covariance, adjusting for BMI.
Results Mean age was 40.8 ± 1.6 years; 98.5% were females. In 60 of the 64 patients, celiac disease was excluded by serology or histology. There were no significant differences in age or BMI among the different HLA-DQ groups. Independently, patients positive for HLA-DQ2 had numerically greater colonic filling at 6 h compared with HLA-DQ2-negative (P = 0.065), and those positive for HLA-DQ8 had greater colonic filling at 6 h compared with HLA-DQ8-negative patients (P = 0.021). Gastric emptying was not associated with HLA-DQ2 and HLA-DQ8 status. Patients positive for both HLA-DQ2 and HLA-DQ8 had greater colonic filling at 6 h (P = 0.013) and numerically higher, but not significant, GC24 (P = 0.38) compared with HLA-DQ2-negative and HLA-DQ8-negative patients. 
Introduction
Irritable bowel syndrome (IBS) is a chronic gastrointestinal condition characterized by recurrent abdominal pain or discomfort with altered bowel habits such as diarrhea. Approximately 46% of patients with diarrhea-predominant IBS (IBS-D) have accelerated colonic transit [1] . It is known that a minority (up to 5%) of patients presenting with symptoms suggestive of IBS-D in community-based or referral centers have celiac disease [2] . Some patients with IBS report an association of symptoms with specific food triggers, suggesting a role of food hypersensitivity [3] [4] [5] . One of these reported food triggers is gluten in the absence of overt celiac disease.
Gluten-sensitive diarrhea without celiac disease was first proposed as a clinical entity in 1980 by Cooper et al. [6] . The spectrum of gluten sensitivity ranges from minimal histological changes such as increased intraepithelial lymphocytes without villous atrophy, increased immunoglobulin A (IgA) deposits in intestinal villi, glutensensitive diarrhea, and immunological mucosal response to gluten exclusion in first-degree relatives of patients with celiac disease [7] . Typically, one or more of these findings are seen in individuals who are positive for human leukocyte antigen (HLA)-DQ2 or HLA-DQ8, suggesting that this entity may be immune mediated, as described previously [7, 8] . Wahnschaffe et al. [8] demonstrated that, among patients with IBS-D, response of diarrhea to a gluten-free diet was influenced by HLA-DQ2 positivity and the presence of IgG tissue transglutaminase (TTG) antibody in duodenal aspirates [9] . Symptom response to gluten withdrawal occurred in 62% of patients positive for both HLA-DQ2 and IgG-TTG; in contrast, only 12% of patients negative for HLA-DQ2 and TTG-IgG responded, suggesting that symptom generation in this subset of patients is immune mediated.
Animal studies have suggested that HLA-DQ8 transgenic mice sensitized to gluten have increased contractile responses of intestinal smooth muscle to electrical field stimulation and to carbachol after gliadin exposure [10] . This increased contractile activity may provide the basis for the development of dysmotility with symptoms suggesting gluten sensitivity. The role of HLA-DQ status in small bowel and colonic motor function in IBS patients has not been established.
Our study hypothesis was that patients with IBS-D who are HLA-DQ2-positive or HLA-DQ8 positive have faster small bowel or colonic transit than HLA-DQ2-negative and HLA-DQ8-negative patients with IBS-D. The aim of this study was to assess small bowel and colonic transit in patients with IBS-D according to their HLA-DQ status. Understanding this relationship has the potential to optimize treatment of a subset of patients with IBS-D.
Materials and methods

Patients and study design
Ninety-four patients with IBS-D were identified from a database of 700 people who were either healthy controls or had been diagnosed with a functional gastrointestinal disorder after clinical evaluation at the Mayo Clinic and had been recruited for previous studies [1, 11] . All participants were residing within 200 miles of the Mayo Clinic, Rochester, Minnesota, USA.
These 94 patients fulfilled the Rome II criteria for diagnosis of IBS-D [12] . Thirty of these patients had not undergone transit measurements; thus, 64 patients had undergone measurements of gastric, small bowel, and colonic transit and were eligible for inclusion. During the transit studies, participants were allowed to continue stable doses of thyroxine, estrogen replacement, low-dose aspirin (81 mg per day), birth control pills or depot estrogen injection, and selective serotonin reuptake inhibitor antidepressants, but not tricyclic agents.
Exclusion criteria included organic diseases that might explain the patients' symptoms, use of any medication for IBS or bowel dysfunction (within 7 days before the study and throughout the course of study), and any structural or metabolic diseases that affect the gastrointestinal system including diabetes. Patients who had participated in another clinical study within the prior 30 days were ineligible.
All individual studies had been approved by the Mayo Clinic Institutional Review Board. Use of the database from which this analysis was conducted was also reviewed and approved by the Mayo Clinic Institutional Review Board, and all participants had authorized use of their medical records and stored DNA for future research studies of gastrointestinal disease.
Evaluation for celiac disease
Patients' medical records were evaluated to assess if celiac disease had been excluded by either serum TTG-IgA and TTG-IgG or duodenal biopsies that were reviewed by an expert gastrointestinal pathologist. For those in whom celiac disease had not been previously excluded, TTG-IgA and TTG-IgG serology was performed on stored serum (N = 33). All participants had provided prior authorization for future use of their serum for research. With the Institutional Review Board permission, some participants with insufficient stored serum were contacted by letter to provide additional serum (N = 9).
Tissue TTG-IgA was measured by a commercially available enzyme immunoassay kit (BINDAZYME Human Anti-Tissue Transglutaminase IgA Kit, The Binding Site Limited, Birmingham B14 4ZB, UK). Tissue TTG-IgG was measured by a commercially available enzyme immunoassay kit (Inova Diagnostics Inc., San Diego, California, USA). Figure 1 shows the method used for transit studies and the specific time points of assessment for each of the measurements. Sixty-four patients had undergone measurements of gastric (N = 50), small bowel (N = 54), and colonic transit (N = 64). Gastric emptying was measured for over 4 h after meal ingestion. One millicurie technetium-99m ( 99m Tc)-sulfur colloid was added to two raw eggs during the scrambling, cooking process as in prior studies [12] . The scrambled eggs were served on one slice of buttered bread with 240 ml of skim milk. The total calorie content of the meal was 296 kcal, and macronutrient composition was 32% protein, 35% fat, and 33% carbohydrate. Anterior and posterior g camera images were obtained immediately after radiolabeled meal ingestion, every 15 min for the first 2 h, then every 30 min for the next 2 h.
Measurement of gastric emptying, small bowel, and colonic transit with scintigraphy
We assessed the colonic filling at 6 h of the 99m Tc egg meal. This serves as a valid surrogate for small bowel transit [13] .
To evaluate colonic transit [14] [15] [16] , indium-111 ( 111 In) adsorbed on activated charcoal particles was delivered to the colon by a methacrylate-coated, delayed-release capsule [15] . All participants ingested the capsule containing 111 In charcoal at 06 : 00 after an overnight fast. When the capsule was demonstrated to have been emptied from the stomach (with images obtained every 30 min while the patient was fasting), all participants received the radiolabeled egg meal at time 0. Two standardized meals were ingested at 4 h (530 kcal chicken meal) and 8 h (750 kcal roast beef sandwich, which includes two slices of bread). We obtained abdominal images every 30 min for the first 10 h, with scans being increased to every 15 min for the first 2 h after meals. A final scan was obtained at 48 h. The performance characteristics of this test are summarized elsewhere [17] .
A variable region of interest program was used to measure isotope counts in each region, and thereby derive a transit measurement, as in previous studies [14] [15] [16] . Geometric means of counts in anterior and posterior gastric regions of interest were used (after correction for radioisotope decay) to estimate the proportion of 99m Tc emptied from the stomach at each time point or filling the colon at 6 h, and the proportion of 111 In in each colonic region at specified times.
Transit data analysis
Gastric emptying endpoint of analysis was t 1 = 2 for solids that was estimated by linear interpolation of the data at each time point. Small bowel transit time was assessed indirectly by the colonic filling at 6 h. Overall colonic transit was summarized as the colonic geometric center (GC) at specified times. The GC is the weighted average of counts in the colonic regions (ascending, transverse, descending, rectosigmoid) and stool, respectively, 1-5. At any time, the proportion of counts in each colonic region is multiplied by its weighting factor as follows: (% ascending Â 1 + % transverse Â 2 + % descending Â 3 + % rectosigmoid Â 4 + % stool Â 5)/100 = GC. Thus, a higher GC reflects a faster colonic transit.
Data on gastric emptying were available for 50 participants, small bowel transit for 54 participants, and colonic transit for all 64 participants. Analysis of associations was based on the available transit data.
Human leukocyte antigen genotyping DNA was extracted from peripheral blood for HLA typing of DR and DQ alleles. High resolution typing of the specific DQ-a and DQ-b alleles, based on a novel HLA genotyping method using six HLA tagging single nucleotide polymorphisms (SNPs), was performed [18] .
Statistical analysis
The association of scintigraphic responses available (50 gastric emptying, 54 small bowel transit, and 64 colonic transit) with HLA-DQ2 and HLA-DQ8 status was assessed using analysis of covariance (ANCOVA), adjusting for BMI for small bowel and colonic transit, and adjusting for sex in the analysis of gastric emptying. The models also included an HLA-DQ2 by HLA-DQ8 crossproduct term to check for potential differential associations for HLA-DQ2 or for HLA-DQ8, given the other genotype. The reported P values for specific pairwise comparisons are not adjusted for three tests (i.e. using the HLA-DQ2/HLA-DQ8 negative/negative group as the 'control group').
Results
Patients and human leukocyte antigen-DQ status
The mean age of the 64 patients with transit measurements was 40.8 ± 1.6 years, and 98.5% were females. Table 1 shows demographic data by the HLA-DQ status. There were no differences in age or BMI among the four groups. Sixty of the 64 patients had serological or duodenal histological exclusion of celiac disease. Serum and duodenal biopsies were not available for four participants.
Twenty-seven of the 64 patients were HLA-DQ2positive, of these 27 patients, 16 were HLA-DQ subtype 2.2 and 11 were HLA-DQ subtype 2.5. Among patients positive for HLA-DQ subtype 2.2, there was one homozygote and 15 heterozygotes. Of the 11 patients positive for HLA-DQ subtype 2.5, there were three homozygotes and eight heterozygotes. The overall efficiency of the HLA SNP assay ranged from 90-100%. The mean allele frequency for each of the six SNPs studied in this cohort was not different from those reported in HapMap CEU (http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi? pop=1409).
Gastric emptying of solids
Fifty patients had t 1 = 2 emptying time for solids. Figure 2 illustrates the gastric emptying data by HLA-DQ2 and HLA-DQ8 status independently. Gastric emptying t 1 = 2 emptying time for solids was 126.3 ± 5.9 min in the HLA-DQ2-positive patients compared with 127.4 ± 7.8 min in the HLA DQ2-negative patients, and 128.6 ± 7.7 min in the HLA-DQ8-positive patients compared with 126.1 ± 6.5 min in the HLA-DQ8-negative patients. HLA-DQ2 or HLA-DQ8 status did not significantly influence gastric emptying time.
Small bowel transit
Fifty-four patients had small bowel transit data expressed as percent of colonic filling at 6 h. Percent colonic filling at 6 h was 56.0 ± 7.4% in HLA-DQ2-positive patients compared with 50.3 ± 4.3% in HLA-DQ2-negative patients, and 62.3 ± 7.2% in HLA-DQ8-positive patients compared with 48.4 ± 4.6% in HLA-DQ8-negative patients (Fig. 3 ). Colonic filling at 6 h in patients positive for HLA-DQ2 was numerically higher (P = 0.065) compared with patients negative for HLA-DQ2. Independently, those positive for HLA-DQ8 had greater percent colonic filling at 6 h (Fig. 2 ) compared with HLA-DQ8-negative (P = 0.021) patients. The ANCOVA indicated that patients positive for both All data shown are mean ± standard error of the mean, unless indicated as N (%). TTG, tissue transglutaminase. HLA-DQ2 and HLA-DQ8 had faster small bowel transit compared with those negative for HLA-DQ2 and HLA-DQ8 ( Table 2 , P = 0.013).
Colonic transit
All the patients had colonic transit measured as GC at 24 h. There was no statistically significant association of colonic transit with patients' HLA-DQ2 or HLA-DQ8 status (P > 0.2). However, the ANCOVA indicated that patients positive for both HLA-DQ2 and HLA-DQ8 had numerically faster colonic transit compared with patients negative for both HLA-DQ2 and HLA-DQ8 (P = 0.013) ( Table 2 ). The analysis also suggested that HLA-DQ8 positivity had a greater impact on colonic transit if HLA-DQ2 was positive than if HLA-DQ2 was negative (P = 0.101 for the HLA-DQ2 by HLA-DQ8 interaction term).
Discussion
Our study shows that patients with IBS-D, positive for either HLA-DQ8 or both HLA-DQ2 and HLA-DQ8 genotypes that are associated with gluten sensitivity, have an accelerated small bowel transit time. Gastric emptying for solids was not influenced by HLA-DQ2 and HLA-DQ8 genotypes. This indicates that the greater colonic filling at 6 h in HLA-DQ8-positive patients reflects accelerated small bowel transit. Colonic transit time was numerically, but not significantly, faster in patients positive for both HLA-DQ2 and HLA-DQ8 alleles.
A number of questions need to be addressed to appraise the data presented here: first, the performance characteristics of the positive result in the study, that is, the association of HLA-DQ status with small bowel transit. Colonic filling at 6 h as a measurement of small bowel transit has been well validated. The reported interpatient coefficient of variation (COV) is approximately 30% and the intrapatient COV is 19% [17] , supporting the robust nature of this test to evaluate small bowel transit. The interpatient and intrapatient COVs are similar for gastric emptying t 1 = 2 , 30.4 and 14%, respectively [12] . It is important to note that gastric emptying was not different among HLA-DQ groups. This is relevant because significant variations in gastric emptying times may impact the interpretation of colonic filling at 6 h. As gastric emptying times were not different by HLA-DQ status in this cohort, the gastric emptying time does not influence the differences observed in colonic filling at 6 h.
We conclude that the association with HLA-DQ status is with small bowel transit in patients with IBS-D.
Second, we needed to appraise the rate of HLA-DQ2 or HLA-DQ8 positivity in the study cohort relative to community controls. Thus, our observed prevalence of HLA-DQ positivity is not higher than that reported for the local Olmsted County population [19] . As expected in a population of patients negative for celiac disease, the HLA-DQ 2.2 and HLA-DQ 2.5 subtypes were rarely homozygotes.
The role of gluten sensitivity and HLA-DQ status in IBS-D is a matter of ongoing research. This study provides further information on the potential mechanisms that may explain symptom generation in this subset of patients. Ongoing prospective studies in our laboratory are addressing the potential effect of several weeks of gluten exclusion in the relief of symptoms and normalization of small bowel transit. Our hypothesis is that an abnormal immune response to gluten evokes chronic inflammation with secondary effects on small bowel motor function in a subset of patients with IBS-D. An alternative hypothesis is that the effect of gluten may be related to the chemical nature of gluten itself, rather than induction of chronic inflammation. Prior studies in patients with IBS have shown that 35% of patients with IBS are HLA-DQ2-positive and, among these patients, 23% had increased intraepithelial lymphocytes and 30% had increased antibodies associated with celiac disease in duodenal aspirates, though there were no such antibodies in serum [8] . The effect of chronic inflammation may be mediated by secreted cytokines. Thus, monocytes from HLA-DQ2-positive patients release two to three times more interleukin-8, a proinflammatory chemokine, than the HLA-DQ2-negative patients [20] . The HLA molecules, present in antigen-presenting cells, determine the major histocompatibility complex-peptide complex that leads to an immune response by binding antigenic peptides, such as gluten, and presents it to a T cell with a subsequent immune response and intestinal inflammation. Under normal circumstances, gluten is not an antigen that produces an immune response. However, in genetically susceptible individuals, the HLA molecules are able to bind gluten and form a major histocompatibility complex. The density and duration of this interaction determine the T cell activation and immune response [21] .
Although several studies in the literature report morphological or functional evidence of inflammation or immune activation in mucosal biopsies from the colorectum as well as the small intestine of patients with IBS [20] , the cause of the inflammation is still incompletely elucidated and bacterial proteases are currently the most favored etiological factor. We believe that further studies are necessary to determine the cause in patients with IBS of the low-grade inflammatory state as illustrated by changes in CD3+ cell counts, mast cell numbers and their proximity to nerves, and reduced serotonin reuptake transporter [22] [23] [24] . The latter has the potential to lead to higher tissue serotonin levels and the associated inflammatory effects of this transmitter [25] . The contribution of these mucosal changes toward the development of gastrointestinal symptoms in patients with IBS-D is the subject of ongoing research.
One potential effect of the low-grade inflammatory state of IBS is abnormal mucosal barrier function through change in the cellular tight junctions, thereby increasing intestinal permeability. This has been previously described in first-degree relatives of patients with celiac disease [26] . Increased intestinal permeability has been documented in vivo in patients with IBS-D and in vitro in mucosa from such patients [27] [28] [29] . However, the cause of the increased permeability is still the subject of research. A soluble factor derived from colonic mucosal biopsies of patients with IBS results in increased permeability of confluent intestinal cells (Caco-2) in culture [29] . A potential role of dietary gluten may also be postulated. Thus, recent studies in celiac disease patients showed that patients with greater histological injury, as indicated by their Marsh classification, had abnormal intestinal permeability and zonulin levels, but had improvement in these factors after long-term gluten-free diet [30] . However, to date, there are no studies on intestinal permeability in susceptible patients with IBS-D with gluten sensitivity or by HLA-DQ status.
The observation of TTG antibodies in intestinal fluid raises the interesting hypothesis that patients with certain HLA status may be susceptible to the production of TTG antibodies locally in the intestine and that this may injure the mucosa, increasing permeability and setting up the cascade of events that ultimately results in accelerated small bowel transit. This is analogous to the observation of Verdu et al. [10] in an animal model where HLA-DQ8 predisposed to the development of motor abnormalities on exposure to gluten. Thus, although human studies are lacking, previous animal studies suggested that HLA-DQ8 transgenic mice that were sensitized to gluten had increased contractile responses in intestinal smooth muscle to electrical field stimulation and carbachol after gliadin exposure [10] .
The pitfalls of this study include its descriptive and retrospective nature, the sample size of participants with transit measurements, and the lack of data on the dietary habits of the patients. Clearly, our study should be regarded as hypothesis generating, and confirmation in replication studies is essential. In order to assess the power of the study, post-hoc estimates of the degree of association that could have been detected with 80% power (two-sided a level = 0.05) and expressed as percent differences between groups defined by HLA-DQ2 status (positive vs. negative) and, separately, DQ8 status (positive vs. negative) are given in Table 3 for each transit measurement. Note that the effect size (difference) in each case is within the range that would be clinically relevant for that endpoint. Therefore, we do not perceive that the sample sizes resulted in a type II error, specifically for those transit profiles that were not significant, that is, gastric emptying and colonic transit.
With regard to dietary habits, it is unknown if any patient in this cohort had been following a gluten-free diet. If they were following such a diet, potentially susceptible patients may have been devoid of symptoms at the time of evaluation. The meals administered in this study did contain bread and gluten. Although the total amount of gluten administered in the test meals was relatively small, we are unable to determine whether the contained gluten actually influenced the transit profile. Serum or tissue was available to exclude celiac disease in 93% of our cohort, and they had normal duodenal biopsies or negative serum TTG-IgA and TTG-IgG. The latter has previously been shown to have strong negative predictive value for celiac disease [31] . The reported prevalence of celiac disease in previously diagnosed patients with IBS-D is less than 5% [32] . Post-hoc estimates of main effect size demonstrable with 80% power (a = 0.05), based on number of participants studied for each regional transit. CF, colonic filling; COV, coefficient of variation; GC, geometric center. a Effect size is 100 Â (difference in means)/(mean overall patients).
Conclusion
In summary, patients with IBS-D positive for HLA-DQ8, or both HLA-DQ2 and HLA-DQ8, have faster small bowel transit. Our data are consistent with the hypothesis that HLA-DQ subtype is an immunogenetic predisposing factor that, upon gluten exposure, leads to acceleration of small bowel transit that is clinically translated in generation of symptoms in IBS patients who do not have celiac disease. The mechanism of the accelerated transit and the potential impact of gluten exposure to small bowel function deserve further investigation.
